Segment Reporting (Tables)

3 Months Ended

May 29, 2021

Segment Reporting

Schedule of balance sheet information for the Company's reportable segments

	Retail		Pharmacy
	Pharmacy		Services		Eliminations(1)		Consolidated
May 29, 2021:
Total Assets	$	6,561,475	$	2,803,665	$	(13,694)	$	9,351,446
Goodwill		43,492		1,064,644		—		1,108,136
February 27, 2021:
Total Assets	$	6,613,370	$	2,736,546	$	(14,512)	$	9,335,404
Goodwill		43,492		1,064,644		—		1,108,136

(1) As of May 29, 2021 and February 27, 2021, intersegment eliminations include netting of the Pharmacy Services segment long-term deferred tax liability of $0 against the Retail Pharmacy segment long-term deferred tax asset for consolidation purposes in accordance with ASC 740, and intersegment accounts receivable of $13,694 and $14,512, respectively, that represents amounts owed from the Pharmacy Services segment to the Retail Pharmacy segment that are created when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products.

Schedule of reconciliation of the Company's business segments to the condensed consolidated financial statements

	Retail		Pharmacy		Intersegment
	Pharmacy		Services		Eliminations(1)		Consolidated
Thirteen Week Period Ended
May 29, 2021:
Revenues	$	4,351,682	$	1,872,282	$	(62,979)	$	6,160,985
Gross Profit		1,169,934		114,941		—		1,284,875
Adjusted EBITDA(2)		94,914		43,963		—		138,877
Additions to property and equipment and intangible assets		60,893		3,707		—		64,600
May 30, 2020:
Revenues	$	4,123,271	$	1,977,246	$	(73,141)	$	6,027,376
Gross Profit		1,081,536		116,783		—		1,198,319
Adjusted EBITDA(2)		62,982		44,410		—		107,392
Additions to property and equipment and intangible assets		36,607		2,567		—		39,174

(1) Intersegment eliminations include intersegment revenues and corresponding cost of revenues that occur when Pharmacy Services segment customers use Retail Pharmacy segment stores to purchase covered products. When this occurs, both the Retail Pharmacy and Pharmacy Services segments record the revenue on a stand-alone basis.

(2) See “Adjusted EBITDA, Adjusted Net Income (Loss), Adjusted Net Income (Loss) per Diluted Share and Other Non-GAAP Measures” in MD&A for additional details.

Schedule of reconciliation of net (loss) income to Adjusted EBITDA

	May 29,		May 30,
	2021		2020
	(13 weeks)		(13 weeks)
Net loss from continuing operations	$	(13,057)	$	(72,702)
Interest expense		49,121		50,547
Income tax expense (benefit)		780		(8,018)
Depreciation and amortization		75,859		79,103
LIFO credit		(3,993)		(12,066)
Facility exit and impairment charges		8,831		3,753
Intangible asset impairment charges		—		29,852
Loss on debt retirements, net		396		—
Merger and Acquisition-related costs		3,886		—
Stock-based compensation expense		2,811		1,874
Restructuring-related costs		5,932		35,735
Inventory write-downs related to store closings		472		834
Litigation settlements		14,000		—
Gain on sale of assets, net		(6,558)		(2,260)
Other		397		740
Adjusted EBITDA from continuing operations	$	138,877	$	107,392